JP2023543978A5 - - Google Patents

Info

Publication number
JP2023543978A5
JP2023543978A5 JP2023516587A JP2023516587A JP2023543978A5 JP 2023543978 A5 JP2023543978 A5 JP 2023543978A5 JP 2023516587 A JP2023516587 A JP 2023516587A JP 2023516587 A JP2023516587 A JP 2023516587A JP 2023543978 A5 JP2023543978 A5 JP 2023543978A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antagonist
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543978A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/050143 external-priority patent/WO2022060678A1/en
Publication of JP2023543978A publication Critical patent/JP2023543978A/ja
Publication of JP2023543978A5 publication Critical patent/JP2023543978A5/ja
Pending legal-status Critical Current

Links

JP2023516587A 2020-09-15 2021-09-14 がん患者を治療するためのpd-1拮抗薬及びlag3拮抗薬及びレンバチニブ又はそれの薬学的に許容される塩の併用療法 Pending JP2023543978A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078485P 2020-09-15 2020-09-15
US63/078,485 2020-09-15
PCT/US2021/050143 WO2022060678A1 (en) 2020-09-15 2021-09-14 Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer

Publications (2)

Publication Number Publication Date
JP2023543978A JP2023543978A (ja) 2023-10-19
JP2023543978A5 true JP2023543978A5 (cg-RX-API-DMAC7.html) 2024-09-25

Family

ID=80777346

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516587A Pending JP2023543978A (ja) 2020-09-15 2021-09-14 がん患者を治療するためのpd-1拮抗薬及びlag3拮抗薬及びレンバチニブ又はそれの薬学的に許容される塩の併用療法

Country Status (9)

Country Link
US (1) US20240010729A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213846A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023543978A (cg-RX-API-DMAC7.html)
KR (1) KR20230069957A (cg-RX-API-DMAC7.html)
CN (1) CN116457016A (cg-RX-API-DMAC7.html)
AU (1) AU2021344849A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195058A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023003032A (cg-RX-API-DMAC7.html)
WO (1) WO2022060678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250064794A1 (en) * 2021-08-10 2025-02-27 Eisai R&D Management Co., Ltd. A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib
WO2025040080A1 (en) * 2023-08-21 2025-02-27 Beigene Switzerland Gmbh Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240064733A (ko) * 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US20190038713A1 (en) * 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
BR112018012352A2 (pt) * 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
WO2019222075A1 (en) * 2018-05-14 2019-11-21 Merck Sharp And Dohme Corp. Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist
JP2021534153A (ja) * 2018-08-15 2021-12-09 アイビバ バイオファーマ インコーポレイテッド Vegfおよびtgfベータのマルチキナーゼ阻害剤およびその使用
WO2020096917A1 (en) * 2018-11-05 2020-05-14 Merck Sharp & Dohme Corp. Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer
JP7503056B6 (ja) * 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体および抗pd-1抗体の共-製剤
JP2023515675A (ja) * 2020-03-05 2023-04-13 メルク・シャープ・アンド・ドーム・エルエルシー Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法

Similar Documents

Publication Publication Date Title
JP2021501162A5 (cg-RX-API-DMAC7.html)
JP2022512851A5 (cg-RX-API-DMAC7.html)
JP2022101693A5 (cg-RX-API-DMAC7.html)
JP2018070648A5 (cg-RX-API-DMAC7.html)
JP2020516240A5 (cg-RX-API-DMAC7.html)
JP2017507900A5 (cg-RX-API-DMAC7.html)
JP2021513540A5 (cg-RX-API-DMAC7.html)
JP2017514795A5 (cg-RX-API-DMAC7.html)
JP2020503273A5 (cg-RX-API-DMAC7.html)
JP2017533912A5 (cg-RX-API-DMAC7.html)
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2018503365A5 (cg-RX-API-DMAC7.html)
JP2020504141A5 (cg-RX-API-DMAC7.html)
JP2017501167A5 (cg-RX-API-DMAC7.html)
JP2018516966A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2017514461A5 (cg-RX-API-DMAC7.html)
JP2018527383A5 (cg-RX-API-DMAC7.html)
JP2022500410A5 (cg-RX-API-DMAC7.html)
RU2018111529A (ru) Комбинированная терапия для лечения рака
JP2018536632A5 (ja) B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子
JP2022512750A5 (cg-RX-API-DMAC7.html)
JP2025092589A5 (cg-RX-API-DMAC7.html)